相似文献
1
Quantification of the Risk of Corticosteroid-induced Diabetes Mellitus Among the Elderly.
J Gen Intern Med. 2002 Sep;17(9):717-20. doi: 10.1046/j.1525-1497.2002.10649.x.
2
Use of inhaled and oral corticosteroids and the long-term risk of cataract.
Ophthalmology. 2009 Apr;116(4):652-7. doi: 10.1016/j.ophtha.2008.12.001. Epub 2009 Feb 25.
3
Inhaled corticosteroids and the risk of diabetes among the elderly.
Br J Clin Pharmacol. 2002 Jul;54(1):59-64. doi: 10.1046/j.1365-2125.2002.01610.x.
4
Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States.
J Am Med Dir Assoc. 2004 Jan-Feb;5(1):38-46.
5
Retrospective review of the incidence of monitoring blood glucose levels in patients receiving corticosteroids with systemic anticancer therapy.
Ann Palliat Med. 2015 Apr;4(2):70-7. doi: 10.3978/j.issn.2224-5820.2015.04.07.
6
Assessment of the Prevalence and Risk Factors Associated With Glucocorticoid-Induced Diabetes Mellitus in Pemphigus Vulgaris Patients.
Acta Med Iran. 2017 Jun;55(6):375-380.
7
The Risk of Sepsis with Inhaled and Oral Corticosteroids in Patients with COPD.
COPD. 2017 Apr;14(2):137-142. doi: 10.1080/15412555.2016.1238450. Epub 2016 Dec 23.
8
Use of inhaled corticosteroids and risk of fractures.
J Bone Miner Res. 2001 Mar;16(3):581-8. doi: 10.1359/jbmr.2001.16.3.581.
9
The relationship between proton pump inhibitor adherence and fracture risk in the elderly.
Calcif Tissue Int. 2014 Jun;94(6):597-607. doi: 10.1007/s00223-014-9855-6. Epub 2014 Apr 6.
10
Proton pump inhibitor use represents an independent risk factor for myocardial infarction.
Int J Cardiol. 2014 Nov 15;177(1):292-7. doi: 10.1016/j.ijcard.2014.09.036. Epub 2014 Sep 28.
引用本文的文献
1
Current Review of Comorbidities in Chronic Rhinosinusitis.
Curr Allergy Asthma Rep. 2024 Nov 19;25(1):4. doi: 10.1007/s11882-024-01184-4.
2
Prednisone use, disease activity and the occurrence of hyperglycaemia and diabetes in patients with early rheumatoid arthritis: a 10-year subanalysis of the BeSt study.
RMD Open. 2024 Apr 30;10(2):e004246. doi: 10.1136/rmdopen-2024-004246.
3
Glucocorticoid-Induced Hyperglycemia: A Neglected Problem.
Endocrinol Metab (Seoul). 2024 Apr;39(2):222-238. doi: 10.3803/EnM.2024.1951. Epub 2024 Mar 27.
4
Prevalence of Steroid-Induced Hyperglycemia in King Abdulaziz Specialist Hospital, Taif City, Saudi Arabia.
Cureus. 2024 Feb 18;16(2):e54430. doi: 10.7759/cureus.54430. eCollection 2024 Feb.
5
Association and Mechanisms of Proton Pump Inhibitors Use with Type-2Diabetes Mellitus Incidence in Adults: A Systemic Review andMeta-Analysis.
Curr Diabetes Rev. 2024;20(10):e120124225581. doi: 10.2174/0115733998254869231101095222.
6
Toxicity evaluation of synthetic glucocorticoids against breast cancer cell lines MDA-MB-231, MCF-7 and human embryonic kidney HEK293.
Med Oncol. 2023 Sep 29;40(11):309. doi: 10.1007/s12032-023-02189-1.
7
Impact of inhaled and intranasal corticosteroids on glucose metabolism and diabetes mellitus: A mini review.
World J Diabetes. 2023 Aug 15;14(8):1202-1211. doi: 10.4239/wjd.v14.i8.1202.
8
Incidence and Severity of Adverse Drug Reactions in Medical Intensive Care Unit.
Curr Drug Saf. 2024;19(3):332-341. doi: 10.2174/1574886318666230816090606.
9
Microbiota-dependent and -independent effects of obesity on transplant rejection and hyperglycemia.
Am J Transplant. 2023 Oct;23(10):1526-1535. doi: 10.1016/j.ajt.2023.06.011. Epub 2023 Jun 23.
10
Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?
Endocr Rev. 2023 Nov 9;44(6):975-1011. doi: 10.1210/endrev/bnad016.
本文引用的文献
1
When should hypertension be treated? The different perspectives of Canadian family physicians and patients.
CMAJ. 2000 Aug 22;163(4):403-8.
2
Deteriorating diabetic control associated with high-dose inhaled budesonide.
Eur Respir J. 1999 Jul;14(1):242-3. doi: 10.1183/09031936.99.141.
3
High dose inhaled corticosteroids and dose dependent loss of diabetic control.
BMJ. 1998 Nov 28;317(7171):1491. doi: 10.1136/bmj.317.7171.1491.
4
Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids.
J Clin Invest. 1997 Oct 15;100(8):2094-8. doi: 10.1172/JCI119743.
5
Post-transplant diabetes mellitus. The role of immunosuppression.
Drug Saf. 1997 Apr;16(4):242-57. doi: 10.2165/00002018-199716040-00002.
6
Information needed to decide about cardiovascular treatment in primary care.
BMJ. 1997 Jan 25;314(7076):277-80. doi: 10.1136/bmj.314.7076.277.
7
Incidence and prevalence of diabetes in Manitoba, 1986-1991.
Diabetes Care. 1996 Aug;19(8):807-11. doi: 10.2337/diacare.19.8.807.
8
Glucocorticoids and the risk for initiation of hypoglycemic therapy.
Arch Intern Med. 1994 Jan 10;154(1):97-101.
9
Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy.
J Intern Med. 1994 Dec;236(6):619-32. doi: 10.1111/j.1365-2796.1994.tb00855.x.
10
Communicating the benefits of chronic preventive therapy: does the format of efficacy data determine patients' acceptance of treatment?
Med Decis Making. 1995 Apr-Jun;15(2):152-7. doi: 10.1177/0272989X9501500208.
Zotero 插件